Articles tagged with Chemotherapy
Researchers at Michigan State University have developed a hydrogel that can be applied to the scalp before chemotherapy treatment, helping to restrict blood flow and prevent hair loss. The temperature-responsive gel is designed to be easily washed off once treatment is complete.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
Cancer cells with abundant circular DNA elements (ecDNA) carrying oncogenes like MYCN are resistant to chemotherapy. Combining standard chemotherapy with a secondary therapy targeting these senescent cells leads to improved outcomes in mouse models of neuroblastoma and medulloblastoma.
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers found that Fen1 protein improves cell tolerance to alovudine by counteracting the toxic effect of 53BP1. This discovery promises new cancer treatments and biomarkers for cancerous cells with Fen1 deficiency.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
A recent study found that a 5 mg dose of olanzapine taken after chemotherapy significantly reduced nausea and vomiting in breast cancer patients, with fewer side effects compared to the standard 10 mg dose. The low-dose regimen was effective for both immediate and delayed symptoms, making it an attractive alternative for patients.
A study documents elite-level strength training during active breast cancer treatment, showing rare retention of squat strength despite chemotherapy. LaShae Rolle, a competitive powerlifter and breast cancer survivor, completed the first-of-its-kind study, demonstrating the feasibility of high-intensity training when carefully managed.
By reprogramming chromatin to prevent cancer cells from adapting to evade treatment, researchers have doubled chemotherapy effectiveness in animal experiments. This approach restores cellular memory, making existing drugs more effective against cancer.
Researchers have discovered a key role of centrosomes in signaling cells to proliferate despite DNA damage, enabling cancer resistance. The study suggests targeting Polo-like kinase 1 could prevent adaptation to therapy-induced DNA damage and drug resistance.
Chemotherapy-induced pyroptosis in bladder cancer can actually make the disease more resistant to treatment by fueling cancer stem cells. Blocking this inflammatory process with belnacasan may overcome chemoresistance in preclinical models.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.
Researchers developed patient-specific Cancer Chips to model esophageal tumor microenvironments, enabling accurate prediction of chemotherapy responses. The approach can rapidly stratify patients into responders and non-responders, paving the way for personalized medicine.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
Researchers at the University of Oklahoma investigate the overlap between cognitive decline caused by chemotherapy and aging, discovering decreased blood flow, disrupted blood-brain barriers, and senescent cells. Removing these cells with senolytics can improve cerebral blood flow, cognition, and overall brain health.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
A study published in The Lancet Global Health found serious quality defects in a significant number of cancer medications from sub-Saharan Africa. Researchers evaluated 251 samples and discovered that one in six medications contained the incorrect quantity of active pharmaceutical ingredient, posing patient safety risks.
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
Researchers have developed a test that can predict chemotherapy resistance in cancer patients, based on chromosomal instability signatures. This test has the potential to personalize treatment and reduce side effects for patients.
A new test developed by CNIO scientists can predict which patients will not respond to common chemotherapy drugs, allowing for targeted treatment and reducing side effects. The test uses biomarkers based on chromosomal instability patterns to identify resistant patients.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
Patients with metastatic colorectal cancer treated with biweekly TAS-102 showed similar treatment effectiveness while experiencing reduced toxicity and lower rates of myelosuppression compared to standard dosing. This alternative schedule may be particularly useful for older patients or those with chemotherapy-related toxicities.
The CompassHER2 trial found that neoadjuvant THP led to a pathologic complete response (pCR) rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer. Lower ER expression levels resulted in higher pCR rates among ER-positive tumors.
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.
Researchers at VCU Massey Comprehensive Cancer Center have identified AEG-1 as the active regulator of inflammation responsible for chemotherapy-induced peripheral neuropathy (CIPN). Eliminating AEG-1 using targeted therapies could provide a critical strategy for managing CIPN in cancer patients.
A $2.4 million grant will fund the development of an optical imaging technology to image nerve endings in cancer patients with chemotherapy-induced peripheral neuropathy. The goal is to identify potential biomarkers for the disease, enabling early detection and prevention.
Researchers at UCSF found that certain gut bacteria can reduce chemotherapy side effects by clearing excess drugs and producing the protective vitamin K2. Patients with more beneficial bacteria had fewer side effects, suggesting that probiotics may help mitigate chemotherapy's impact.
A research team from the University of Copenhagen has developed a biotechnological method to produce Taxol, a widely used cancer drug. The new method involves cloning taxol-producing genes and inserting them into yeast cells, making it more cost-effective and sustainable than traditional chemical synthesis.
A nationwide cohort study found that immune checkpoint inhibitors significantly increase the risk of myocarditis in NSCLC patients, with a 7.4-fold increase in risk compared to non-users. Cardiac monitoring for at least six months following ICI initiation is recommended.
A new clinical trial has shown that a lower dose of radiotherapy can lead to higher levels of complete disappearance of cancer and fewer short-term side effects. The treatment approach, led by Professor David Sebag-Montefiore, aims to reduce the burden on patients and healthcare systems.
DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy, pinpointing mutational escape routes that let cancers resist treatment. The framework reveals which genes may ignite resistance to anticancer drugs, suggesting a core circuitry boosting strategy.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
A new study suggests that multi-strain probiotics can alleviate chemotherapy-related side effects such as fatigue, nausea, and weakness. Probiotics have been shown to improve blood urea nitrogen levels and enable patients to perform daily activities more independently.
A study found that satisfying intimate relationships and general social support can reduce cognitive problems experienced by breast cancer patients undergoing chemotherapy. The research suggests that couples therapy could be a helpful option for partnered patients, while oxytocin levels decreased significantly during treatment.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
Scientists have developed a cutting-edge technology to analyze protein turnover in individual cells, enabling them to identify treatment-resistant cancer cells and understand the impact of specific drugs. This breakthrough could lead to advancements in disease diagnostics and treatment strategies.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
Researchers developed DNA origami structures that selectively deliver fluorescent imaging agents to pancreatic cancer cells, enabling more accurate cancer imaging and selective chemotherapy delivery. The study also explored the use of origami-folded DNA molecules loaded with chemotherapy drugs for targeted delivery to cancer cells.
Recent studies have improved the diagnostic accuracy of CUP, surpassing 90%, with advancements in methodologies such as gene expression profiling. Site-specific therapies have shown significant benefits over empirical chemotherapy, leading to improved patient outcomes for those affected by this condition.
Adapted Argentine tango dance therapy is helping some breast cancer survivors regain natural balance and sensation after experiencing neuropathy, a common side effect of chemotherapy treatment. The therapy aims to rewire the brain to improve function after chemotherapy-related nerve changes.
Researchers developed a saliva test that uses AI to identify genetic mutations in the DPYD gene, which can affect how well cancer patients respond to chemotherapy. The study found several new mutations that could lead to severe side effects from 5-fluorouracil, a widely used chemotherapy drug.
Scientists at the University of Birmingham have made strides in understanding how cells repair DNA damage. Two studies identify key players and mechanisms involved in preventing excessive DNA signal overload, which could lead to refinements in future cancer therapies.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
New research reveals changes in brain connectivity during chemotherapy in breast cancer patients, particularly in the frontal-limbic system and cerebellar cortex. These changes worsen as treatment continues, suggesting that chemotherapy can quickly disrupt brain function in breast cancer patients.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
Researchers developed bacteria-enhanced graphene oxide nanoparticles that effectively destroy tumors through a three-pronged mechanism. The nanocomposites combine chemotherapy, immune activation, and photothermal heating to suppress tumor growth and activate strong immune responses in mice.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
Researchers at Mass General Brigham have identified mutations in VPS35 that can prevent chemotherapy-induced cell death, leading to treatment-resistant tumors. Higher tumoral VPS35 levels were associated with improved treatment responses and overall survival rates in patients with ovarian cancer.
Researchers have identified six promising biomarkers that can detect drug-induced kidney injury earlier than traditional markers, enabling more timely monitoring during drug development. These biomarkers could lead to the development of safer medications and improve patient outcomes.
Researchers have developed a way to activate adult stem cells from human bone marrow, enabling their expansion outside the body for use in bone marrow regeneration. The new method significantly improves transplant success rates for patients with genetic disorders or those who require a bone marrow transplant.
A single-arm trial evaluated the safety and efficacy of first-line camrelizumab, apatinib, and chemotherapy in untreated extensive-stage small-cell lung cancer patients. The treatment demonstrated an ORR of 88.9% and median PFS and OS of 7.3 and 17.3 months, respectively.
Breast cancer survivors experience accelerated aging due to detrimental effects of BC and its treatments, particularly systemic therapies. The study highlights the need for ongoing monitoring and potential strategies to slow down aging in cancer survivors.
A new bacterial protein, BeeR, has been identified and its structure is being used to develop protein nanoparticles for targeted cancer drug delivery. The protein forms a hollow tube with a cavity capable of containing drug molecules.
Engineered platelets-based nano-aircraft carriers enhance targeted chemotherapy with graded drug release, promoting antitumor immune response and reducing metastasis. Researchers successfully develop Pts-based nanovesicles for precise cancer treatment.
A phase 1 clinical trial led by City of Hope demonstrated the safety and early efficacy of targeted chemotherapy using PIPAC combined with systemic chemotherapy for patients with colorectal and appendiceal cancer that has spread to the peritoneum of the abdominal cavity. The study showed promising results, including histologic, laparos...
A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.
A recent study by Professor Mamas highlights the significant risk of cardiovascular diseases (CVD) in patients with cancer, particularly in aging populations. The review emphasizes the need for early diagnosis and regular monitoring to improve quality of life.